Bacterial Infections clinical trials
The registry lists 584 studies for Bacterial Infections across more than 10 countries. 84 are recruiting or about to start. 335 of them are mainly about Bacterial Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 57 narrower conditions too, such as Tuberculosis: 6,387 studies, 1,028 open.
ClinicalTrials.gov finds 8,203 studies for Bacterial Infections. How that becomes 583 here
This page counts the studies the registry files under Bacterial Infections, and those it files under no condition that list Bacterial Infectionsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 8,203Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −5,519Filed under a narrower condition, counted on its own pageTuberculosis 1,136 · Tetanus 297 · Pneumococcal Infections 288 · Hidradenitis Suppurativa 282 · Staphylococcal Infections 281 · Clostridium Infections 240 · 49 more
- −109List Bacterial Infections as a condition, but the registry did not file them under itMost often written as “Bacterial Infection Due to Helicobacter Pylori (H. Pylori)” (13), “Bacterial Infections and Mycoses” (10), and “Urinary Tract Infection Bacterial” (10). The registry filed 39 of them under no condition at all, and the others under other conditions only, most often Bacterial Infections and Mycoses (10) and Urinary Tract Infections (7).
- −1,992Match it another way64 name it in the title, 10 in a keyword, and 1,918 by a synonym or other text the search reads.
- 583The count on this page
Get an email when these change. Save the Bacterial Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
GlaxoSmithKline (35) · National Institute of Allergy and Infectious Diseases (NIAID) (17) · Wyeth is now a wholly owned subsidiary of Pfizer (15) · Pfizer (13) · Qpex Biopharma, Inc. (9) · Merck Sharp & Dohme LLC (8) · Assistance Publique - Hôpitaux de Paris (7) · Radboud University Medical Center (6)
What is being tested here
Drugs under test in Bacterial Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Amoxicillin | 2 | 0 | 5 |
| Gepotidacin | 1 | 0 | 11 |
| Levofloxacin | 1 | 5 | 6 |
| Clindamycin | 1 | 0 | 5 |
| Fosfomycin | 1 | 0 | 3 |
| Ciprofloxacin | 1 | 1 | 3 |
| Eravacycline | 1 | 0 | 2 |
| Clavulanic Acid | 1 | 0 | 2 |
| Metronidazole | 1 | 0 | 2 |
| Rifaximin | 1 | 0 | 2 |
Drug classes tested here Beta-lactamase inhibitors 3 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Feb 2027A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) · Phase 3 · CanSino Biologics Inc.
- Nov 2026Molecular Culture for the Diagnosis of Pediatric Sepsis · Jip Groen
- Dec 2026Large Algorithm Setting and Validation Study · Nanopath, Inc
- Dec 2026Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Children Meningitis · Hospital Israelita Albert Einstein
- Dec 2026Therapeutic Options for CRAB · Clinical Hospital Centre Zagreb
- Dec 2026Clinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Dec 2026An Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED. · The University of Texas Health Science Center, Houston
- Feb 2027Impact of Procalcitonin-guided Algorithm on Early Discontinuation of Antibiotic Therapy · University Hospital, Toulouse
- Mar 2027Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis (SURVIC_STUDY) · Eva Bonfill
- Mar 2027Development and Evaluation of Rapid Bacterial Species Identification for Acid-Fast Bacilli Smear Using Image Analysis AI · GramEye
Who these studies take
Of the 56 Bacterial Infections studies recruiting now, 37 (66%) set no upper age limit and 14 (25%) stop at 75 or younger. 19 (34%) take children under 18. 1 (2%) are for women only and 0 (0%) for men only; 6 (11%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 13 (23%) | 13 (23%) |
| 18 | 47 (84%) | 46 (82%) |
| 30 | 46 (82%) | 45 (80%) |
| 40 | 46 (82%) | 45 (80%) |
| 50 | 44 (79%) | 43 (77%) |
| 65 | 43 (77%) | 42 (75%) |
| 75 | 43 (77%) | 42 (75%) |
| 85 | 42 (75%) | 41 (73%) |
Across all 584 studies, recruiting or not: 39% stop at 75 or younger and 36% at 65; 32% take children; 4% are for women only and 2% for men only; 29% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Bacterial Infections studies take
Of 67 phase 1 interventional studies under Bacterial Infections, half reached primary completion within 9 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 9 mo4–15 · 67 studies | 8 mo3–13 · 52 studies | — |
| Phase 3 | 24 mo19–41 · 28 studies | — | — |
| Phase 4 | 22 mo15–64 · 18 studies | — | — |
| Interventional, no phase | 25 mo11–43 · 60 studies | — | 25 mo11–43 · 56 studies |
| Observational | 22 mo12–38 · 80 studies | — | 23 mo12–44 · 73 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Stopped1
- Integrated Clinical Decision Support for Empiric Antibiotic Selection in SepsisTerminatedOct 19, 2026NCT06103500
Studies
Recruiting first, then most recently updated. Showing 50 of 584. Browse all 584 → or search them.
- Fosfomycin Trometamol Compared With an Alternative Active Antibiotic as Step-down Therapy for the Treatment of Acute Pyelonephritis Due to Escherichia Coli in Elderly Women : a Randomized, Multicenter, Non-inferiority TrialNot yet recruitingNCT07928063Phase 3
- KInetics of Procalcitonin to Reduce Unnecessary aNtibiotic Use - Comparing Procalcitonin Kinetics-guided and Absolute Procalcitonin Value-guided Antibiotic Initiation in Reducing Unnecessary Antibiotic Use in Critically Ill PatientsRecruitingNCT07211620Not applicable1 country
- Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in PediatricsRecruitingNCT07111793Not applicable1 country
- A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaRecruitingNCT05645107Phase 38 countries
- A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis AntibioticsNot yet recruitingNCT07371429Phase 11 country
- Microbiology Operations & Time Optimization in SepsisNot yet recruitingNCT078170431 country
- Differentiating True Nephrotoxicity From Pseudo-nephrotoxicity: A Prospective Comparative Study of Vancomycin Plus Piperacillin-Tazobactam vs. Meropenem Using Serum Creatinine and Cystatin-CNot yet recruitingNCT078182651 country
- [18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human SubjectsRecruitingNCT04263792Phase 11 country
- Biomarkers of Phage Treatment Response in NTM and Other InfectionsRecruitingNCT070762381 country
- Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute DiarrheaRecruitingNCT07285785Phase 41 country
- Impact of Procalcitonin-guided Algorithm on Early Discontinuation of Antibiotic TherapyRecruitingNCT05350813Not applicable1 country
- A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)Not yet recruitingNCT07648641
- Large Algorithm Setting and Validation StudyRecruitingNCT076074701 country
- First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected PatientsRecruitingNCT07708116Phase 11 country
- Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis (SURVIC_STUDY)RecruitingNCT05783661Phase 41 country
- Personalized Antibiotic Therapy - Point-of-Care Determination of Blood Levels of Beta-Lactam Antibiotics Using Coated-Blade-Spray Ion Mobility SpectrometryNot yet recruitingNCT07666230
- Impact of Culture of Perfusion Fluid on Donor-derived Infection Management and Outcome in Liver and Kidney TransplantNot yet recruitingNCT076511371 country
- Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?RecruitingNCT019041881 country
- Clinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic PatientsRecruitingNCT076121631 country
- Emergency PWAS in Respiratory Infectious DiseaseRecruitingNCT053368511 country
- Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Children MeningitisRecruitingNCT070624451 country
- Diagnostic Performance of a Combination of Leukocyte Cell Surface Markers in Predicting the Risk of Severe Bacterial Infection in Febrile Children Under Three Months of Age in the Emergency Department: a Pilot Study.RecruitingNCT066189891 country
- Prospective Clinical Study, Using a Medical Device (RepHegyn) as an Adjuvant in the Treatment of Fungal (Candidiasis) and Bacterial InfectionsNot yet recruitingNCT073672951 country
- Healthrelated Quality of Life and Experiences of a Heart Rehabilitation Programme After Care for Infective Endocarditis.RecruitingNCT06704048Not applicable1 country
- Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.RecruitingNCT05993442Not applicable5 countries
- Subcutaneous Piperacillin/Tazobactam Compared With Intravenous TreatmentRecruitingNCT07481539Phase 21 country
- Viromes in Infants Presenting With a Septic SyndromeNot yet recruitingNCT07470541Not applicable1 country
- Observational Study of Raxibacumab in Sporadic Cases of Systemic AnthraxNot yet recruitingNCT07478471
- Efficacy of Fusidic Acid 1% in the Treatment of Bacterial ConjunctivitisRecruitingNCT06911424Phase 31 country
- Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxNot yet recruitingNCT03569514
- Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioNot yet recruitingNCT02177721Phase 4
- A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsNot yet recruitingNCT03569553
- Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised OutpatientsRecruitingNCT07110636Not applicable1 country
- An Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED.RecruitingNCT06070688Not applicable1 country
- Therapeutic Options for CRABRecruitingNCT06440304Phase 41 country
- A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese WomenNot yet recruitingNCT07302035Phase 11 country
- Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and FeverRecruitingNCT07051525Not applicable1 country
- Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years OldRecruitingNCT07204457Phase 2/31 country
- CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)RecruitingNCT05846399Phase 41 country
- Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy VolunteersRecruitingNCT07207291Phase 11 country
- Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency RoomRecruitingNCT061788221 country
- Evaluation of the Dialytic Clearance of the Combination of Peracillin and TazobactamNot yet recruitingNCT071675241 country
- Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial InfectionNot yet recruitingNCT07146217Phase 21 country
- Diagnostic Application of AI-ROSE in Severe PneumoniaEnrolling by invitationNCT071139511 country
- Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas AeruginosaRecruitingNCT070568811 country
- The AcCREDiT 2 StudyNot yet recruitingNCT070296721 country
- Application of Bacterial DNA Quantitative Detection in Diagnosis of SBP in Cirrhosis: A Multi Center Diagnostic ExperimentEnrolling by invitationNCT069958461 country
- Impact of Early Antibiotics on Non-Traumatic Out of Hospital Cardiac Arrest (OHCA)RecruitingNCT05914779Not applicable1 country
- Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression/transcript Abundance, Direct LS-TA. a Prospective Study Will Evaluate the Performance of Direct LS-TA in Triage Febrile Patients Into Major Categories of Infections: Viral, Bacterial or Active Tuberculosis.Not yet recruitingNCT068466451 country
- Combination of Leukocyte Cell Surface Biomarkers Measured by Cytometry, to Differentiate Bacterial From Viral Infections in Emergency Department: a Multicentric Cohort for the Validation of Diagnostic PerformancesRecruitingNCT061552661 country